商业通讯
请输入关键词
  • 首页
  • 资讯
  • 科技
  • 财商
  • 汽车
  • 家电
  • 生活
 > 资讯

Coventry’s LILY Funding Program Reaches $1 Billion in Life Insurance-Backed Financing

发布于:2026-08-25 21:00:02 来源:Coventry

FORT WASHINGTON, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Coventry, the leader and creator of the secondary market for life insurance and a pioneer of the life insurance-backed asset class, today announced the successful completion of its fourth asset-backed securitization since April 2025 under its LILY program, bringing total life insurance-backed financing across the platform to $1 billion. This achievement further establishes Coventry as the leading platform for institutional investors seeking differentiated exposure to longevity-linked assets.

This milestone also reflects continued investor demand for longevity-linked assets and LILY’s growing role as one of the industry’s leading platforms for accessing life insurance-backed investments through the asset-backed securities market.

Since its launch in 2025, the LILY program has consistently demonstrated the ability to access institutional capital by structuring longevity-linked assets into investment-grade asset-backed securities that emphasize durable collateral, predictable cash flows, and low correlation with traditional markets. The program combines Coventry’s extensive origination capabilities, actuarial expertise, servicing infrastructure, and transaction structuring experience to provide investors with access to a specialized asset class through a familiar ABS format.

“Reaching the $1 billion mark is a significant milestone for the LILY program and for the institutional market for life insurance-backed assets,” said Reid Buerger, Chief Executive Officer of Coventry. “More importantly, it reflects growing investor recognition of the value of longevity-linked assets and the benefits of accessing them through a disciplined, repeatable securitization platform like LILY. We believe this achievement reflects both the quality of the underlying assets and the strength of the infrastructure Coventry has built to originate, analyze, service, and finance them at scale.”

The growth of the LILY program underscores Coventry’s position at the intersection of life insurance, asset-backed finance, and private credit. As institutional investors continue to seek differentiated sources of return and portfolio diversification, Coventry expects life insurance-backed financing to play an increasingly important role in supporting the responsible expansion of the longevity-linked asset market.

To learn more about the LILY program and other Coventry updates, please visit www.coventry.com/news

About Coventry
Coventry is the leader and creator of the secondary market for life insurance and a pioneer of the life insurance-backed asset class, operating an integrated platform across four complementary verticals: the secondary market for life insurance, longevity lending, life insurance and annuity distribution, and insurance technology. Through these businesses, Coventry expands financial options for policyowners, provides capital solutions backed by life insurance policies and other longevity-linked assets, broadens access to insurance and retirement products, and applies technology to enhance pricing, risk management, and operational efficiency across the life insurance ecosystem.

Guided by a longstanding commitment to consumer rights and market integrity, Coventry leverages its leadership position to raise industry standards, expand consumer choice, and responsibly develop institutional-quality life insurance-backed investment solutions. Over its history, Coventry has acquired more than 23,000 life insurance policies, completed more than $50 billion in longevity-linked transactions, delivered more than $6 billion to policyowners, and originated more than $1 billion in life insurance-linked loans. To learn more about Coventry, visit Coventry.com.

Media Contact:
Jonny Shiver
Vice President, Marketing
jshiver@coventry.com
(215) 836-8300

 

上一篇:U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in Fir

下一篇:

热门文章

  • Omdia:iPhone用户在微短剧上的消费比安卓安卓用户高出40%

    2026-08-14
  • 光影致敬实业奋斗者——《有你真好1》观影暨《再创新辉煌》有奖征文活动启事

    2026-06-30
  • 维权落地资产安全稳固 药易购经营底盘稳健蓄力数智化长期增长

    2026-08-06
  • 派逊亮相2026年江苏省中小学生实验能力大赛总决赛,助力“实践育人”

    2026-08-03
  • 从生产计划到仓储管理,勤哲Excel服务器提升制造业管理效率

    2026-08-04
  • 杭叉集团举办首届AI DAY科技日 正式发布LogiMind具身大模型与全系列叉车机器人

    2026-07-23

本站部分文字及图片均来自于网络,如有侵权请及时联系删除处理

Copyright ©2023-2024 商业通讯.Powered by © hubeizhichuang.com